MedDataX Logo

Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021

NCT ID: NCT07302607

Last Updated: 2025-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

221 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-11

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage III Melanoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Stage III Melanoma Immunotherapy in Metastatic Melanoma Metastatic melanoma (unresectable stage III and IV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years;
* Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
* Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
* Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
* Immunotherapy initiated between January 1, 2013, and December 31, 2021.

Exclusion Criteria

* Primary choroidal melanoma;
* Adjuvant-intent immunotherapy;
* Less than 3 months of follow-up after the start of immunotherapy;
* Change of treatment before the first reassessment;
* Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de dermatologie - Réanimation - CHU de Strasbourg - France

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cédric LENORMAND, MD

Role: CONTACT

Phone: 33 3 88 11 66 27

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Cédric LENORMAND, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9453

Identifier Type: -

Identifier Source: org_study_id